ZIOPHARM ONCOLOGY INC Contracts & Agreements
141 Contracts & Agreements
- Business Finance (37 contracts)
- Business Operations (16)
- Human Resources (49)
- Intellectual Property (9)
- Mergers & Acquisitions (1)
- Real Estate (5)
- Uncategorized (24)
- Consulting Agreement, dated as of November 14, 2023, between the Registrant and Melinda Lackey (Filed With SEC on April 1, 2024)
- Separation Agreement, dated as of December 22, 2023, between the Registrant and Kevin S. Boyle, Sr (Filed With SEC on April 1, 2024)
- Consulting Agreement, dated as of December 22, 2023, between the Registrant and Kevin S. Boyle, Sr (Filed With SEC on April 1, 2024)
- Consulting Agreement, dated as of February 21, 2024, between the Registrant and Ferdinand Groenewald (Filed With SEC on April 1, 2024)
- Retention Agreement, dated as of August 14, 2023, between the Registrant and Melinda Lackey (Filed With SEC on November 14, 2023)
- Retention Agreement, dated as of August 14, 2023, between the Registrant and Drew Deniger (Filed With SEC on November 14, 2023)
- Underwriting Agreement, dated as of November 29, 2022, by and between Alaunos Therapeutics, Inc. and Cantor Fitzgerald & Co (Filed With SEC on November 30, 2022)
- Fourth Amendment to the Cooperative Research and Development Agreement, dated June 24, 2022, by and between the National Cancer Institute and the Registrant (Filed With SEC on August 15, 2022)
- Equity Distribution Agreement, dated August 12, 2022, by and between Piper Sandler & Co. and the Registrant (Filed With SEC on August 15, 2022)
- Form of Warrant to Purchase Shares of Common Stock issued to SVB and certain of its Affiliates, dated December 28, 2021 (Filed With SEC on March 30, 2022)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 30, 2022)
- Employment Agreement, dated April 23, 2019, by and between the Registrant and Jill Buck (Filed With SEC on March 30, 2022)
- Amendment to Employment Agreement, dated November 23, 2020, by and between the Registrant and Jill Buck (Filed With SEC on March 30, 2022)
- Employment Agreement, dated April 23, 2019, by and between the Registrant and Eleanor de Groot (Filed With SEC on March 30, 2022)
- Amendment to Employment Agreement, dated November 23, 2020, by and between the Registrant and Eleanor de Groot (Filed With SEC on March 30, 2022)
- Employment Agreement, dated September 30, 2020, by and between the Registrant and Raffaele Baffa (Filed With SEC on March 30, 2022)
- Amendment to Employment Agreement, dated November 23, 2020, by and between the Registrant and Raffaele Baffa (Filed With SEC on March 30, 2022)
- Third Amendment to Patent License Agreement, dated as of April 16, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
- Fourth Amendment to Patent License Agreement, dated as of May 4, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
- Fifth Amendment to Patent License Agreement, dated as of August 13, 2021, by and between the Registrant and the National Cancer Institute (Filed With SEC on March 30, 2022)
- Third Amendment to the Cooperative Research and Development Agreement, dated March 15, 2022, by and among the National Cancer Institute and the Registrant (Filed With SEC on March 30, 2022)
- First Amendment to the Loan and Security Agreement by and among the Registrant, the lenders party thereto and Silicon Valley Bank, as administrative agent and collateral agent,... (Filed With SEC on March 30, 2022)
- Separation Agreement, dated March 28, 2022, by and between the Registrant and Dr. Raffaele Baffa (Filed With SEC on March 30, 2022)
- Form of Warrant to Purchase Shares of Common Stock dated August 6, 2021 (Filed With SEC on November 8, 2021)
- Loan and Security Agreement by and among the Registrant, the lenders party thereto and Silicon Valley Bank, as administrative agent and collateral agent, dated August 6, 2021 (Filed With SEC on November 8, 2021)
- Employment Agreement by and between ZIOPHARM Oncology, Inc. and Kevin S. Boyle, Sr., dated August 24, 2021 (Filed With SEC on August 30, 2021)
- Separation Agreement by and between the Company and Dr. Laurence Cooper, dated April 5, 2021 (Filed With SEC on April 9, 2021)
- Consulting Agreement by and between the Company and Dr. Laurence Cooper, entered into on April 5, 2021 (Filed With SEC on April 9, 2021)
- Employment Agreement by and between Ziopharm Oncology, Inc. and Heidi Hagen, dated February 25, 2021 (Filed With SEC on March 2, 2021)
- Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 1, 2021)
- Form of Stock Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 1, 2021)
- Amendment to the Employment Agreement by and between the Registrant and Robert Hadfield, dated as of November 23, 2020 (Filed With SEC on March 1, 2021)
- Amendment to the Employment Agreement by and between the Registrant and Sath Shukla, dated as of November 23, 2020 (Filed With SEC on March 1, 2021)
- Form of Retention Bonus Agreement (Filed With SEC on March 1, 2021)
- Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson... (Filed With SEC on March 1, 2021)
- First Amendment, dated as of April 7, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of Regents... (Filed With SEC on March 1, 2021)
- Second Amendment, dated as of April 7, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of... (Filed With SEC on March 1, 2021)
- Third Amendment, dated as of December 15, 2020, to the Lease Agreement, dated as of October 15, 2019, by and between the Registrant and The University of Texas System Board of... (Filed With SEC on March 1, 2021)
- Lease Agreement dated as of December 15, 2020, by and between the Registrant and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson... (Filed With SEC on March 1, 2021)
- Consulting Agreement by and between Ziopharm Oncology Inc. and Danforth Advisors LLC, effective as of January 21, 2021 (Filed With SEC on February 23, 2021)
- Agreement, by and among ZIOPHARM Oncology, Inc., WaterMill Asset Management Corp. Robert W. Postma, Jamie Vieser, and Holger Weis, dated February 4, 2021 (Filed With SEC on February 5, 2021)
- Second Amendment to Patent License Agreement, dated as of September 28, 2020, by and between the Registrant and the National Cancer Institute (Filed With SEC on November 5, 2020)
- Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020 (Filed With SEC on November 5, 2020)
- Ziopharm Oncology, Inc. 2020 Equity Incentive Plan (Filed With SEC on July 1, 2020)
- Consulting Agreement by and between the Company and Dr. David Mauney, dated May 26, 2020 (Filed With SEC on May 29, 2020)
- Separation Agreement and Release by and between the Company and Dr. David Mauney, effective May 26, 2020 (Filed With SEC on May 29, 2020)
- Warrant to Purchase Common Stock issued to The University of Texas M. D. Anderson Cancer Center (Filed With SEC on March 2, 2020)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act Of 1934, as amended (Filed With SEC on March 2, 2020)
- Fifth Amendment to Research and Development Agreement, dated October 22, 2019 by and among the Registrant and The University of Texas MD Anderson Cancer Center (Filed With SEC on March 2, 2020)
- 2019 Research and Development Agreement, dated October 22, 2019, by and between the Registrant and The University of Texas MD Anderson Cancer Center (Filed With SEC on March 2, 2020)
- Amendment to Patent License Agreement, dated as of January 8, 2020 , by and between the Company and the National Cancer Institute (Filed With SEC on March 2, 2020)
- Underwriting Agreement by and between Ziopharm Oncology, Inc. and Jefferies LLC, dated February 5, 2020 (Filed With SEC on February 6, 2020)
- Fourth Amendment to Research and Development Agreement, dated September 19, 2019 by and between the Registrant, The University of Texas MD Anderson Cancer Center and Precigen, Inc (Filed With SEC on November 7, 2019)
- Cooperative Research and Development Agreement, dated January 9, 2017, by and among the National Cancer Institute, Ziopharm Oncology, Inc. and Intrexon Corporation (Filed With SEC on September 26, 2019)
- Amendment #1 to the Cooperative Research and Development Agreement, dated March 23, 2018, by and among the National Cancer Institute, Ziopharm Oncology, Inc., Intrexon Corporation... (Filed With SEC on September 26, 2019)
- Amendment #2 to the Cooperative Research and Development Agreement, dated February 1, 2019, by and among the National Cancer Institute, Ziopharm Oncology, Inc. and Precigen, Inc (Filed With SEC on September 26, 2019)
- Form of New Warrant to Purchase Common Stock (September 2019) (Filed With SEC on September 13, 2019)
- Form of Securities Issuance Agreement (September 2019) (Filed With SEC on September 13, 2019)
- Form of Registration Rights Agreement (September 2019) (Filed With SEC on September 13, 2019)
- Patent License Agreement, dated as of May 28, 2019, by and between the Company and the National Cancer Institute (Filed With SEC on August 8, 2019)
- Form of New Warrant to Purchase Common Stock (Filed With SEC on August 1, 2019)
- Form of Securities Issuance Agreement (Filed With SEC on August 1, 2019)
- Form of Registration Rights Agreement (Filed With SEC on August 1, 2019)
- Placement Agency Agreement, dated July 26, 2019, by and among Ziopharm Oncology, Inc. and Raymond James & Associates, Inc (Filed With SEC on August 1, 2019)
- Employment Agreement by and between Ziopharm Oncology, Inc. and Sath Shukla (Filed With SEC on July 24, 2019)
- Inducement Award Agreement by and between Ziopharm Oncology, Inc. and Sath Shukla (Filed With SEC on July 24, 2019)
- Employment Agreement, dated as of April 23, 2019, by and between the Company and David Mauney, M.D (Filed With SEC on April 29, 2019)
- Employment Agreement, dated as of April 23, 2019, by and between the Company and Robert Hadfield (Filed With SEC on April 29, 2019)
- Amendment #1 to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of August... (Filed With SEC on March 5, 2019)
- Amendment #2 to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of... (Filed With SEC on March 5, 2019)
- Amendment #3 to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of... (Filed With SEC on March 5, 2019)
- Form of Warrant to Purchase Common Stock (Filed With SEC on November 13, 2018)
- Form of Securities Purchase Agreement (Filed With SEC on November 13, 2018)
- Form of Registration Rights Agreement (Filed With SEC on November 13, 2018)
- Placement Agency Agreement, dated November 11, 2018, by and among Ziopharm Oncology, Inc. and Raymond James & Associates, Inc (Filed With SEC on November 13, 2018)
- Exclusive License Agreement by and between the registrant, Precigen, Inc. and Intrexon Corporation, dated October 5, 2018 (Filed With SEC on November 9, 2018)
- Ziopharm Oncology, Inc. 2012 Equity Incentive Plan, as amended (Filed With SEC on September 24, 2018)
- Separation Agreement by and between ZIOPHARM Oncology, Inc. and Caesar J. Belbel dated as of February 15, 2018 (Filed With SEC on February 22, 2018)
- Offer Letter by and between ZIOPHARM Oncology, Inc. and David M. Mauney, M.D (Filed With SEC on September 28, 2017)
- Severance Agreement by and between ZIOPHARM Oncology, Inc. and David M. Mauney, M.D (Filed With SEC on September 28, 2017)
- Inducement Award Agreement by and between ZIOPHARM Oncology, Inc. and David M. Mauney, M.D (Filed With SEC on September 28, 2017)
- ZIOPHARM Oncology, Inc. 9,708,738 Shares of Common Stock Underwriting Agreement (Filed With SEC on May 12, 2017)
- EXCLUSIVE CHANNEL PARTNER AGREEMENT (Filed With SEC on February 16, 2017)
- THIRD AMENDMENT TO EXCLUSIVE CHANNEL PARTNERAGREEMENT (Filed With SEC on June 30, 2016)
- AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATIONAGREEMENT (Filed With SEC on June 30, 2016)
- SECURITIES ISSUANCE AGREEMENT (Filed With SEC on June 30, 2016)
- EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (Filed With SEC on October 1, 2015)
- RESEARCH AND DEVELOPMENT AGREEMENT (Filed With SEC on August 21, 2015)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on June 2, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on May 7, 2015)
- Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A... (Filed With SEC on April 2, 2015)
- SECOND AMENDMENT TO EXCLUSIVE CHANNEL PARTNERAGREEMENT (Filed With SEC on April 2, 2015)
- ZIOPHARM Oncology, Inc. 10,000,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on February 4, 2015)
- LICENSE AGREEMENT (Filed With SEC on January 28, 2015)
- SECURITIES ISSUANCE AGREEMENT (Filed With SEC on January 14, 2015)
- SECURITIES ISSUANCE AGREEMENT (Filed With SEC on January 14, 2015)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on January 14, 2015)
- ZIOPHARM ONCOLOGY, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 7, 2012 APPROVED BY THE STOCKHOLDERS: JUNE 20, 2012 AMENDED BY THE BOARD OF DIRECTORS:... (Filed With SEC on August 7, 2014)
- ZIOPHARM ONCOLOGY, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 7, 2012 APPROVED BY THE STOCKHOLDERS:JUNE 20, 2012 AMENDED BY THE BOARD OFDIRECTORS:... (Filed With SEC on June 19, 2014)
- AMENDED AND RESTATED SEVERANCE AGREEMENT (Filed With SEC on May 8, 2014)
- AMENDMENT AND EXTENSION TO EMPLOYMENT AGREEMENT (Filed With SEC on January 8, 2014)
- AMENDMENT TO EMPLOYMENTAGREEMENT (Filed With SEC on January 8, 2014)
- ZIOPHARMOncology, Inc. 14,300,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on October 29, 2013)
- EXTENSION OF EMPLOYMENT AGREEMENT (Filed With SEC on January 8, 2013)
- ZIOPHARMOncology, Inc. 2012Equity Incentive Plan Adoptedby the Board of Directors: March 7, 2012 Approvedby the Stockholders: June 20, 2012 (Filed With SEC on June 26, 2012)
- ZIOPHARMOncology, Inc. 2012Equity Incentive Plan Formof Restricted Stock Agreement (Filed With SEC on June 26, 2012)
- ZIOPHARMOncology, Inc. 2012 Equity Incentive Plan Form of Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) (Filed With SEC on June 26, 2012)
- EMPLOYMENTAGREEMENT (Filed With SEC on May 10, 2012)
- FIRST AMENDMENT TO EXCLUSIVE CHANNELPARTNER AGREEMENT (Filed With SEC on May 3, 2012)
- ZIOPHARM ONCOLOGY, INC. AmendmentNo. 1 to EmploymentAgreement (Filed With SEC on April 3, 2012)
- ZIOPHARM Oncology, Inc. 9,650,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on January 25, 2012)
- EMPLOYMENT AGREEMENT (Filed With SEC on September 6, 2011)
- EMPLOYMENT AGREEMENT (Filed With SEC on July 15, 2011)
- EMPLOYMENT AGREEMENT (Filed With SEC on June 3, 2011)
- ZIOPHARM ONCOLOGY, INC. AMENDED AND RESTATED 2003 STOCK OPTION PLAN (Amended and restated as of September 1, 2010) (Filed With SEC on March 1, 2011)
- Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on March 1, 2011)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 1, 2011)
- 9,600,000Shares ZIOPHARMONCOLOGY, INC. CommonStock ($0.001par value per Share) UNDERWRITINGAGREEMENT (Filed With SEC on February 7, 2011)
- AMENDMENTTO STOCKPURCHASE AGREEMENT (Filed With SEC on February 7, 2011)
- ExclusiveChannel Partner Agreement (Filed With SEC on January 12, 2011)
- STOCKPURCHASE AGREEMENT (Filed With SEC on January 12, 2011)
- EXTENSIONOF EMPLOYMENT AGREEMENT (Filed With SEC on December 28, 2010)
- 7,000,000Shares ZIOPHARMONCOLOGY, INC. CommonStock ($0.001par value per Share) UNDERWRITINGAGREEMENT (Filed With SEC on June 2, 2010)
- 15,484,000Shares Warrantsto Purchase 7,742,000Shares ZIOPHARMOncology, Inc. CommonStock ($0.001par value) UNDERWRITINGAGREEMENT (Filed With SEC on December 8, 2009)
- Formof Underwriters Warrant ZIOPHARMONCOLOGY, INC. WARRANTTO PURCHASE COMMON STOCK (Filed With SEC on December 8, 2009)
- ZIOPHARMONCOLOGY, INC. WARRANTTO PURCHASE COMMON STOCK (Filed With SEC on September 15, 2009)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on September 15, 2009)
- REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on September 15, 2009)
- EMPLOYMENT AGREEMENT (Filed With SEC on July 30, 2008)
- Form of Restricted Stock Agreement ZIOPHARM Oncology, Inc. Restricted Stock Agreement (Filed With SEC on December 18, 2007)
- EMPLOYMENT AGREEMENT EXTENSION (Filed With SEC on June 19, 2007)
- ZIOPHARM ONCOLOGY, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on February 26, 2007)
- ZIOPHARM ONCOLOGY, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on February 26, 2007)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on February 26, 2007)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 26, 2007)
- EMPLOYMENT AGREEMENT EXTENSION (Filed With SEC on December 26, 2006)
- THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on May 3, 2006)
- Form of Placement Agent Warrant (Filed With SEC on May 3, 2006)
- SUBSCRIPTION AGREEMENT (Filed With SEC on May 3, 2006)
- ZIOPHARM Oncology, Inc. Amendment No. 1 to 2003 Stock Option Plan (Filed With SEC on April 26, 2006)
- Agreement and Plan of Merger dated August 3, 2005 (Filed With SEC on August 9, 2005)